Fulcrum Therapeutics, Inc. Common Stock (FULC)

Price$6.42

Value ScoreC

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-53.36%

Price vs S&P 500 (4W)-10.95%

VGM Score49.25

Market Capitalization$461.10M

All Metrics

Book Value / Share (Quarterly)$5.00

P/TBV (Annual)1.29x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)61.03%

Cash Flow / Share (Quarterly)$-0.96

Price vs S&P 500 (YTD)-49.75%

Net Profit Margin (TTM)8.13%

EPS (TTM)$-0.90

10-Day Avg Trading Volume0.41M

EPS Excl Extra (TTM)$-0.90

EPS (Annual)$-1.18

ROI (Annual)-21.46%

Net Profit Margin (5Y Avg)-1288.02%

Cash / Share (Quarterly)$5.00

ROA (Last FY)-20.44%

EBITD / Share (TTM)$-0.99

ROE (5Y Avg)-32.06%

Operating Margin (TTM)-3.60%

Cash Flow / Share (Annual)$-0.91

P/B Ratio1.38x

P/B Ratio (Quarterly)1.53x

Net Income / Employee (Annual)$-1,361,500

EV / Revenue (TTM)5.03x

ROA (TTM)-21.19%

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)27.40x

Quick Ratio (Quarterly)33.97x

3-Month Avg Trading Volume0.89M

52-Week Price Return-2.12%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.13

P/S Ratio (Annual)5.76x

Asset Turnover (Annual)0.31x

52-Week High$15.74

Operating Margin (5Y Avg)-1396.58%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-25.19%

Tangible BV CAGR (5Y)172.58%

26-Week Price Return-37.43%

Quick Ratio (Annual)27.08x

13-Week Price Return-20.73%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)34.33x

Enterprise Value$410.84M

Asset Turnover (TTM)0.29x

Book Value / Share Growth (5Y)8.97%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-12.16%

Cash / Share (Annual)$5.29

3-Month Return Std Dev64.16%

Net Income / Employee (TTM)$-1,040,500

ROE (Last FY)-21.46%

EPS Basic Excl Extra (Annual)$-1.18

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.90

Receivables Turnover (Annual)0.00x

ROI (TTM)-22.54%

P/S Ratio (TTM)5.65x

Pretax Margin (5Y Avg)-1288.02%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.82

Price vs S&P 500 (52W)-30.33%

Year-to-Date Return-38.82%

5-Day Price Return5.33%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-28.96%

Net Profit Margin (Annual)-12.16%

Month-to-Date Return-2.95%

Cash Flow / Share (TTM)$-1.64

EBITD / Share (Annual)$-1.32

Operating Margin (Annual)-27.37%

ROI (5Y Avg)-32.06%

EPS Basic Excl Extra (TTM)$-0.90

P/TBV (Quarterly)1.00x

P/B Ratio (Annual)2.14x

Pretax Margin (TTM)8.13%

Book Value / Share (Annual)$5.24

Price vs S&P 500 (13W)-30.48%

Beta2.93x

Revenue / Share (TTM)$0.00

ROE (TTM)-22.54%

52-Week Low$5.88

vGradeC

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.25est. -0.30

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.06

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
FULCFulcrum Therapeutics, Inc. Common Stock	C	—	D	$6.42
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for genetically defined rare diseases. Its lead candidate, Pociredir, is an oral drug designed to induce fetal hemoglobin in patients with sickle cell disease; Phase 1b data demonstrated clinically meaningful HbF induction and improvements in hemolysis and anemia markers. The company maintains a pipeline of additional clinical and preclinical programs targeting the root causes of rare genetic disorders.